| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.086 | 0.1 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.091 | 0.1 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.13 | 0.1 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.1 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.1 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |